ea0063gp193 | Adrenal and Neuroendocrine - Clinical | ECE2019
Pilli Tania
, Cardinale Sandro
, Forleo Raffaella
, Cantara Silvia
, Ferracin Manuela
, Bassi Cristian
, Negrini Massimo
, Grazia Castagna Maria
Background: Conventional treatment (cortisone acetate or hydrocortisone) of adrenal insufficiency (AI) is potentially associated with glycometabolic alterations, bone loss and reduced quality of life. There is an increasing evidence of a more physiological replacement therapy with modified-release hydrocortisone (Plenadren).AimThe objectives of our study were: 1) to compare the gene expression profile of patients under conventional treatment and Plenadren versus healthy contro...